secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001683168-25-002245
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.
- Net proceeds of approximately $1.8M after deducting offering expenses; funds to be used for general corporate purposes and working capital.
- Pre-funded warrants exercisable immediately at $0.001 per share; expire when exercised in full.
- Offering closed on April 3, 2025; Aegis Capital acted as exclusive placement agent.
- Pricing was at the market under Nasdaq rules; shelf registration statement effective January 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316825002245/0001683168-25-002245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316825002245/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-002245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer